or Try an Advanced Search...

    Hematopoietic Stem Cell Stocks List

    Symbol Grade Name % Change
    JSPR C Jasper Therapeutics, Inc 0.21
    PRTC C PureTech Health plc 0.53
    CMRX D Chimerix, Inc. 1.14
    FATE F Fate Therapeutics, Inc. -4.50
    NTLA F Intellia Therapeutics, Inc. 6.94
    ATNM F Actinium Pharmaceuticals, Inc. 0.00
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biology Biopharmaceutical Biotechnology Life Sciences Stem Cell Hematologic Malignancies Immunology Medicine Monoclonal Antibody Transplantation Actinides Acute Myeloid Leukemia Adult Stem Cell Alzheimer's Disease Amyloid Amyloidosis Antibodies Antitrypsin Deficiency Antiviral Drug Antivirals

    Related ETFs - A few ETFs which own one or more of the above listed Hematopoietic Stem Cell stocks.

    Symbol Grade Name Weight
    ARKG F ARK Genomic Revolution Multi-Sector ETF 3.89
    GNOM F Global X Genomics & Biotechnology ETF 3.23
    ARKK B ARK Innovation ETF 2.09
    HRTS D Tema Cardiovascular and Metabolic ETF 1.66
    WDNA D WisdomTree BioRevolution Fund 1.6
    View all Hematopoietic Stem Cell ETFs...
    Compare ETFs
    Compare ARKG to ARKK Compare GNOM to HRTS Compare GNOM to WDNA

        Hematopoietic Stem Cell Stocks Recent News

        Date Stock Title
        Nov 20 FATE Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
        Nov 20 PRTC PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
        Nov 19 NTLA Intellia Therapeutics Announces Promising CRISPR Therapy Results
        Nov 19 NTLA ReCode to secure funds for cystic fibrosis gene correction treatments
        Nov 19 FATE Wall Street Breakfast Podcast: Fate Therapeutics Rises On Lupus Drug Data
        Nov 19 NTLA Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo
        Nov 19 NTLA Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
        Nov 18 FATE Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results
        Nov 18 FATE Fate stock rallies 37% on positive Phase 1 data for FT819, FT522
        Nov 18 NTLA Intellia’s gene editing therapy shows early potential in rare heart condition
        Nov 18 FATE Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
        Nov 18 FATE Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
        Nov 18 NTLA CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
        Nov 16 NTLA Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
        Nov 16 JSPR We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate
        Nov 15 FATE Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
        Related Industries: Biotechnology
        Related Stock Lists: Biology Biopharmaceutical Biotechnology Life Sciences Stem Cell Hematologic Malignancies Immunology Medicine Monoclonal Antibody Transplantation Actinides Acute Myeloid Leukemia Adult Stem Cell Alzheimer's Disease Amyloid Amyloidosis Antibodies Antitrypsin Deficiency Antiviral Drug Antivirals
        Hematopoietic Stem Cell

        Hematopoietic stem cells (HSCs) are a type of stem cell that can differentiate into all types of blood cells, including red blood cells, white blood cells, and platelets. HSCs are found in the bone marrow and are responsible for the production of all types of blood cells throughout a person's life.

        Browse All Tags